Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780

Savarese, Diane; Halabi, Susan; Hárs, Vera; Akerley, Wallace; Taplin, Mary‐Ellen; Godley, Paul A.; Hussain, Arif; Small, Eric J.; Vogelzang, Nicholas J.

doi:10.1200/jco.2001.19.9.2509

Cited by 316 publications

(203 citation statements)

References 19 publications

Supporting

Mentioning

178

Contrasting

Unclassified

Order By: Relevance

“…The median duration of the palliative response was about 10 months, which is similar to that recently observed with the use of mitoxantrone + prednisone or taxotere, and longer than that found with prednisone alone, vinorelbine or paclitaxel (Tannock et al, 1996;Fields-Jones et al, 1999;Trivedi et al, 2000;Savarese et al, 2001). The palliative response was accompanied by an improvement in a number of the quality of life dimensions, particularly a reduction in pain and an improvement in functional scales.…”

Section: Discussionsupporting

confidence: 84%

“…Most previous studies have found little evidence of anti-tumour activity, with response rates of less than 10% for single chemotherapeutic agents and similar results for combination therapies (Eisenberger et al, 1985;Millikan, 1999). However, more recent studies with mitoxantrone, docetaxel and estramustine have shown a response (Tannock et al, 1996;Savarese et al, 2001). It is difficult to assess the effectiveness of chemotherapeutic agents in the treatment of metastatic prostate cancer because the patients often do not have measurable disease (Coleman, 1998).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Weekly epirubicin in patients with hormone-resistant prostate cancer

et al. 2002

View full text Add to dashboard Cite

The aim of this study was to investigate the benefit of weekly epirubicin in the treatment of metastatic hormone-resistant prostate cancer. One hundred and forty-eight patients with metastatic hormone-resistant prostate cancer received weekly 30-min intravenous infusions of epirubicin 30 mg m 2 of body surface area. The primary end-point was palliative response, defined as a reduction in pain intensity and an improvement in performance status. The secondary end-points were the duration of the palliative response, quality of life and survival. Fifty-seven (44%) of the 131 evaluable patients met the primary criterion of palliative response after six treatment cycles and 73 (56%) after 12 cycles; the median duration of the response was 9 months (range 1 -11). The median global quality of life improved in 52% of the patients after six cycles and in 68% after 12 cycles. The 12-and 18-month survival rates were respectively 56 and 31%, with a median survival of 13+ months (range 1 -36). The treatment was well tolerated: grade 3 neutropenia was observed in 8% of the patients, grade 3 anaemia in 7%, and grade 3 thrombocytopenia in 3%. None of the patients developed grade 4 toxicity or congestive heart failure. Weekly epirubicin chemotherapy can lead to a rapid and lasting palliative result in patients with metastatic HRPC, and have a positive effect on the quality of life and survival.

show abstract

Section: Discussionsupporting

confidence: 84%

mentioning

confidence: 99%

Weekly epirubicin in patients with hormone-resistant prostate cancer

et al. 2002

View full text Add to dashboard Cite

show abstract

“…After palliative responses were seen in two randomized studies that involved mitoxantrone and corticosteroid, this became the only FDA-approved chemotherapeutic combination for metastatic prostate cancer 67,68 . Other combination therapies have included agents such as estramustine, vincristine, etoposide, doxorubicin, and the taxanes paclitaxel and docetaxel [69][70][71][72][73] . Emerging clinical data indicate a survival advantage in patients treated with these newer chemotherapy combinations who have a significant fall (that is, >50-75%) in serum PSA 74 .…”

Section: Cytotoxic Chemotherapymentioning

confidence: 99%

A history of prostate cancer treatment

2002

View full text Add to dashboard Cite

The increased incidence of prostate cancer has led to remarkable changes in diagnosis and treatment over the past century. What were the first ways in which prostate cancer was treated, and how did these evolve into the variety of therapeutic strategies from which patients have to choose today?In 1853, J. Adams, a surgeon at The London Hospital, described the first case of prostate cancer, which he discovered by histological examination 1 . Adams noted in his report that this condition was "a very rare disease". Remarkably, 150 years later, prostate cancer has become a significant health problem. In the United States, it is the most commonly diagnosed cancer in men, with 180,000 new cases and about 31,000 deaths occurring annually 2 . This dramatic increase in the number of prostate cancer cases can be attributed to several causes. First, prostate cancer was not differentiated from other types of urinary obstruction until the early 1900s. Second, the incidence of prostate cancer increases more rapidly with age than any other cancer type 2 . The number of cases has risen as the average life expectancy has increased over the past century. Third, the increased incidence seems to be, in some way, related to the 'Western' lifestyle: the incidence of clinical prostate cancer is significantly lower in Asian populations, compared with Western populations 3 , and it

show abstract

“…In fact, besides vinorelbine, 22,23 several studies have combined a taxane with estramustine with encouraging results in terms of response rate and survival. [24][25][26][27] However, significant toxicity was again observed in all of these studies. The thrombotic complications have been a source of concern for many investigators and have resulted in prophylactic regimens being introduced into the trials, with the aim of mitigating this toxicity.…”

Section: Discussionmentioning

confidence: 85%

Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer — a phase II trial

Bernardi

Talamini

Zanetti

et al. 2004

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

A total of 28 patients were treated with mitoxantrone, vinorelbine and prednisone every 3 weeks. In all, 11 patients (46%) had a significant prostate-specific antigen decline for a median duration of 11.4 months. Eight patients (33%) achieved a partial response on pain, while seven (29%) obtained a stabilisation of the symptom. Median duration of the response was 9.5 months. A confirmed partial response was obtained in three out of seven patients who had bidimensionally measurable disease. Toxicity was manageable. Our study provides further support to the concept of combined antimicrotubule therapy for metastatic harmonoresistant prostate cancer, promoting the exploration of new regimens containing antimicrotubule agents in addition to mitoxantrone-prednisone.

show abstract

Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780

Abstract: This therapy is efficacious and moderately well tolerated in HRPC and should be compared in a phase III trial with mitoxantrone and prednisone.

Cited by 316 publications

References 19 publications

Weekly epirubicin in patients with hormone-resistant prostate cancer

Weekly epirubicin in patients with hormone-resistant prostate cancer

A history of prostate cancer treatment

Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer — a phase II trial

Contact Info

Product

Resources

About